Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

C2269000

Clindamycin phosphate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Clindamycin 2-phosphate, Clindamycin 2-dihydrogen phosphate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H34ClN2O8PS
Numéro CAS:
24729-96-2
Poids moléculaire :
504.96
Numéro CE :
246-433-0
Numéro MDL:
MFCD07793328
Code UNSPSC :
41116107
ID de substance PubChem :
329774986
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

clindamycin

Fabricant/nom de marque

EDQM

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O

InChI

1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1

Clé InChI

UFUVLHLTWXBHGZ-MWBQRTRKSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clindamycin phosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Antibacterial and antiprotozoal antibiotic of the licosamide class.
Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H317,H319,H362

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

Ciprofloxacin hydrochloride European Pharmacopoeia (EP) Reference Standard

C2190000

Ciprofloxacin hydrochloride

Clindamycine hydrochloride lincosamide antibiotic

Sigma-Aldrich

C5269

Clindamycine hydrochloride

Permethrin European Pharmacopoeia (EP) Reference Standard

Y0001733

Permethrin

Cefotaxime sodium salt suitable for plant cell culture, BioReagent, powder or crystals

Sigma-Aldrich

C7039

Cefotaxime sodium salt

Lawrence F Eichenfield et al.
Pediatric dermatology, 26(3), 257-261 (2009-08-27)
Treatments for mild to moderately severe acne usually combine retinoid and antimicrobial therapy. Recently, the US FDA approved the combination of 1.2% clindamycin (CLIN) and 0.025% tretinoin (RA) in a novel gel formulation for the treatment of mild to moderate
M Badawy Abdel-Naser et al.
Expert opinion on pharmacotherapy, 9(16), 2931-2937 (2008-10-22)
Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The
Diane Thiboutot et al.
Journal of the American Academy of Dermatology, 59(5), 792-800 (2008-09-23)
We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were
Azadeh Ghaffari et al.
International wound journal, 9(2), 221-229 (2011-12-08)
Ethanol that affects hydration of skin and used in wound treatment formulations was studied here for its effect on permeation of drugs through burn eschar and to investigate the presence of a porous pathway in this barrier. In this study
Asuka Munehiro et al.
The Journal of dermatological treatment, 23(3), 172-176 (2011-07-16)
Cosmetic moisturisers were applied to one side of the face of 18 male Japanese patients with acne vulgaris who were treated with a topical administration of adapalene and clindamycin phosphate gels. We assessed the alleviating effect of the moisturisers on
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique